Full-length serine protein kinase in brain and pancreas

• US 6,455,292 B1
• Filed: 08/16/2001
• Issued: 09/24/2002
• Est. Priority Date: 08/16/2001
• Status: Active Grant

• Current Assignee: Origene Technologies Incorporated
• Original Assignee: Origene Technologies Incorporated
• Inventors: Zidanic, Michael, Fan, Wufang, Jay, Gilbert, Kovacs, Karl F., Shu, Youmin
• Primary Examiner(s): Murthy, Ponnathapuachuta
• Assistant Examiner(s): RAMIREZ, DELIA M
• Application Number:
  US09/930,181
• Time in Patent Office: 404 Days
• Field of Search: 435/194, 435/320.1, 435/252.3, 435/15, 435/325, 536/23.2
• US Class Current: 435/194
• CPC Class Codes: C12N 9/1205 Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
• CPC Class Codes: G01N 2333/9121 with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes

Abstract

The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine. The polynucleotides are expressed in brain and pancreas and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to diseases and conditions, especially relating to brain and pancreas.

Claims

1. An isolated polynucleotide which codes without interruption for a human KSE336 polypeptide as set forth in SEQ ID NO:

2 or SEQ ID NO;

4, or a complete complement thereto.

3. The isolated polynucleotide of claim 1, comprising the sequence set forth in SEQ ID NO:

1.

4. The isolated polynucleotide of claim 1, comprising the sequence set forth in SEQ ID NO:

3.

5. A method for identifying an agent that modulates the expression of a polynucleotide encoding human KSE336 in brain cells, pancreas cells, brain progenitor cells, or pancreas progenitor cells, said method comprising,

a) contacting a cell population comprising said cells with a test agent under conditions effective for said test agent to modulate the expression of the polynucleotide of claim 1;

and,

b) determining whether said test agent modulates the expression of said polynucleotide.

6. The method of claim 5, wherein said agent is an antisense polynucleotide to a target polynucleotide sequence within SEQ ID NO:

1 which is effective to inhibit translation of said human KSE336.

2. An isolated polynucleotide which has 99% or more sequence identity to a polynucleotide as set forth in SEQ ID NO:

1 or 3, or a complete complement thereto, wherein said polynucleotide encodes for a human KSE336 polypeptide having serine/threonine protein kinase activity.